Background: Agomelatine modulates brain-derived neurotrophic factor expression via its interaction with melatonergic and serotonergic receptors and has shown promising results in terms of brain-derived neurotrophic factor increase in animal models. Methods: Twenty-seven patients were started on agomelatine (25 mg/d). Venous blood was collected and brain-derived neurotrophic factor serum levels were measured at baseline and after 2 and 8 weeks along with a clinical assessment, including Hamilton Depression Rating Scale and Snaith-Hamilton Pleasure Scale. Results: Brain-derived neurotrophic factor serum concentration increased after agomelatine treatment. Responders showed a significant increase in brain-derived neurotrophic factor levels after 2 weeks of agomelatine treatment; no difference was observed in nonresponders. Linear regression analysis showed that more prominent brain-derived neurotrophic factor level variation was associated with lower baseline BDNF levels and greater anhedonic features at baseline. Conclusions: Patients affected by depressive disorders showed an increase of brain-derived neurotrophic factor serum concentration after a 2-week treatment with agomelatine. The increase of brain-derived neurotrophic factor levels was found to be greater in patients with lower brain-derived neurotrophic factor levels and marked anhedonia at baseline.

Martinotti, G., Pettorruso, M., De Berardis, D., Varasano, P. A., Pressanti, G. L., De Remigis, V., Valchera, A., Ricci, V., Di Nicola, M., Janiri, L., Biggio, G., Di Giannantonio, M., Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms, <<INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY>>, 2016; 19 (5): pyw003-N/A. [doi:10.1093/ijnp/pyw003] [http://hdl.handle.net/10807/94655]

Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms

Martinotti, Giovanni
;
Pettorruso, Mauro
Secondo
;
Ricci, Valerio;Di Nicola, Marco;Janiri, Luigi;Di Giannantonio, Massimo
Ultimo
2016

Abstract

Background: Agomelatine modulates brain-derived neurotrophic factor expression via its interaction with melatonergic and serotonergic receptors and has shown promising results in terms of brain-derived neurotrophic factor increase in animal models. Methods: Twenty-seven patients were started on agomelatine (25 mg/d). Venous blood was collected and brain-derived neurotrophic factor serum levels were measured at baseline and after 2 and 8 weeks along with a clinical assessment, including Hamilton Depression Rating Scale and Snaith-Hamilton Pleasure Scale. Results: Brain-derived neurotrophic factor serum concentration increased after agomelatine treatment. Responders showed a significant increase in brain-derived neurotrophic factor levels after 2 weeks of agomelatine treatment; no difference was observed in nonresponders. Linear regression analysis showed that more prominent brain-derived neurotrophic factor level variation was associated with lower baseline BDNF levels and greater anhedonic features at baseline. Conclusions: Patients affected by depressive disorders showed an increase of brain-derived neurotrophic factor serum concentration after a 2-week treatment with agomelatine. The increase of brain-derived neurotrophic factor levels was found to be greater in patients with lower brain-derived neurotrophic factor levels and marked anhedonia at baseline.
Inglese
Martinotti, G., Pettorruso, M., De Berardis, D., Varasano, P. A., Pressanti, G. L., De Remigis, V., Valchera, A., Ricci, V., Di Nicola, M., Janiri, L., Biggio, G., Di Giannantonio, M., Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms, <<INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY>>, 2016; 19 (5): pyw003-N/A. [doi:10.1093/ijnp/pyw003] [http://hdl.handle.net/10807/94655]
File in questo prodotto:
File Dimensione Formato  
94655OA.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 891.92 kB
Formato Unknown
891.92 kB Unknown Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/94655
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 50
social impact